Epic Bio to Participate in the BMO Virtual Spotlight Series

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas protein, today announced that the company will be participating in the BMO Virtual Spotlight Series: Epigenome Editing, on November 21, 2022. Amber Salzman, Ph.D., chief executive officer, and Dan Hart, Ph.D., head of technology development, are … Read more

Epic Bio Presents First Data Supporting Persistent and Tunable Gene Activation Using Transient Delivery   

– New activator in the GEMS (Gene Expression Modulation System) Platform addresses limitations of existing therapy modalities –– Persistent activation of genes may provide permanent cure for diseases such as haploinsufficient diseases –– Tunable protein expression mitigates the risk of toxic overexpression – SOUTH SAN FRANCISCO, Calif. — October 31, 2022 — Epic Bio, a biotechnology company … Read more

Epic Bio to Participate in the 6th International Conference on Epigenetics and Bioengineering 

SOUTH SAN FRANCISCO, Calif. — October 24, 2022 — Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced its participation at the 6th International Conference on Epigenetics and Bioengineering, held in Houston, Texas, taking place October 27 – 29, 2022.  ICEB 2022 Presentation Details:  Poster Presentation Title: GEMS: … Read more

Epic Bio Presents Proprietary Gene Expression Modulation System (GEMS) Demonstrating Precise Engineering of DUX4 Gene in Facioscapulohumeral Muscular Dystrophy

SOUTH SAN FRANCISCO, Calif. – October 13, 2022 – Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced a presentation on the company’s unique engineering platform, called the Gene Expression Modulation System (GEMS), at the co-hosted Solebury / BMO Fall Private Company Showcase. “We are excited … Read more

Epic Bio to Participate in the Solebury / BMO Fall Private Company Showcase

SOUTH SAN FRANCISCO, Calif. — October 6, 2022 — EPIC BIO, a biotechnology company developing therapies to modulate gene expression using the compact, non-cutting dCas protein, today announced that the company will be participating in the Solebury / BMO Fall Private Company Showcase, taking place Thursday, October 13, 2022, in New York. The event is co-hosted by … Read more

Epic Bio, Founded by CRISPR Pioneer, Launches to Revolutionize Genetic Medicine with Epigenetic Engineering

– $55 million Series A financing will advance the company’s robust preclinical pipeline and ongoing discovery efforts –  – Epic holds exclusive license to smallest known Cas protein, enabling in vivo delivery via AAV vector to wide range of target organs – –  Lead program in facioscapulohumeral muscular dystrophy (FSHD) on track for clinical initiation … Read more